A Phase 2 interventional study of Meloxicam 7.5 mg and Meloxicam 3.75 mg in Pain, sponsored by Boehringer Ingelheim. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-07-08.
Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing meloxicam in Pain — 1 open to participants now, 1 under way, none of them phase 3. Meloxicam · Pain.
Among the 10 studies testing meloxicam in Pain, this one is the 2nd largest by enrollment, is the only one that started in 1998, is one of 2 in phase 2, and was the 1st registered.
10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.
Browse Pain studies →1 of the 10 studies testing meloxicam in Pain is open now, in 1 country. Recruiting first, the newest first:
St. Louis University · Sites in United States
Ages 13–50
By country, each count listing its studies:
Meloxicam: first FDA approval 2000 (MOBIC), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 1 started in 1998.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 381 is above the median of 66 across 8,505 interventional studies indexed under Pain.
Median enrollment 210 across the 10 interventional studies. Of the 8 that completed or were terminated, 6 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 10 have an industry lead sponsor. The 5 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Boehringer Ingelheim has 8 studies filed under Pain — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing meloxicam in Pain, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To assess the analgesic efficacy and tolerability of meloxicam 15 mg, 7.5 mg, 3.75 mg and 1.875 mg oral (rapid release tablet) compared with placebo and ibuprofen 400 mg and 200 mg administered in a single dose, over an observation period of 6 hours in the treatment of pain after surgery of the third molar.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Placebo · Drug: Meloxicam 15 mg
Drug: Meloxicam 7.5 mg · Drug: Placebo
Drug: Meloxicam 3.75 mg · Drug: Placebo
Drug: Meloxicam 1.875 mg · Drug: Placebo
Drug: Placebo · Drug: Ibuprofen 400 mg
Drug: Ibuprofen 200 mg · Drug: Placebo
Drug: Placebo
Assessment of pain intensity differences (PID) on a visual analogue scale (VAS, 100 mm) from one hour onwards
Time frame: 60, 90, 120, 180, 240, 300 and 360 minutes after drug administration
Assessment of PID on a VAS
Time frame: Up to 360 minutes after drug administration
Sum of pain intensity differences (SPID)
Time frame: Up to 360 minutes after drug administration
Number of patients with pain decrease >=50%
Time frame: Up to 360 minutes after drug administration
Assessment of maximum pain decrease on a VAS
Time frame: Up to 360 minutes after drug administration
Number of withdrawals due to safety reasons
Time frame: Up to 7 days after drug administration
Number, nature and severity of adverse events
Time frame: Up to 7 days after drug administration
Total pain relief (TOTPAR) assessed by patient (Area under the pain relief-by time curve)
Time frame: Up to 360 minutes after drug administration
Assessment of onset of analgesic action
Time frame: Up to 2 hours after surgery
Final assessment of efficacy by patient on a 4-point verbal rating scale (VRS)
Time frame: 6 hours after drug administration
Final assessment of efficacy by investigator on a 4-point VRS
Time frame: 2 hours after drug administration
Change from baseline in laboratory values
Time frame: Baseline, up to 7 days after drug administration
Assessment of the progress of healing of the extraction site
Time frame: 3-7 days after drug administration
Patient's assessment of overall tolerability on a 4-point rating scale
Time frame: Day 7 after drug administration
Investigator's assessment of overall tolerability on a 4-point rating scale
Time frame: Day 7 after drug administration
Pain relief assessed by patient on a 5-point VRS
Time frame: Up to 360 minutesafter drug administration
Number of withdrawals due to inadequate efficacy
Time frame: Up to 7 days after drug administration
No study locations are listed for this record.
The record gives a start of Apr 1998 and a primary completion of Oct 1998. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Meloxicam · Ibuprofen